Australia, March 24 -- Seaport Therapeutics Inc., owns the trademark (2583203) for 'GLYPHAGO' till Sept. 3, 2035.
Status: registered:
Registered/protected
Classes: 5 [Technologies in the nature of pharmaceutical preparations of drugs that facilitate the delivery of pharmaceutical compounds for oral administration of therapeutics utilizing the lymphatic system to treat human and animal disease and illness, namely infectious diseases, inflammatory disorders, respiratory diseases, cardiovascular diseases, autoimmune disorders, gastrointestinal disorders, cancer, hematological diseases, neurological diseases, neuropsychiatric disorders, hepatic diseases, renal diseases, lymphatic disorders, metabolic disorders, genetic disorders, dermatological disorders, ocular diseases, and orphan diseases.], 35 [Commercialization, namely, commercial consultancy in the pharmaceutical and biotechnology fields.] and 42 [Research and development in the pharmaceutical and biotechnology fields; medical and scientific research in the field of clinical trials.]
Type of Mark: Word
Date of Acceptance: Sept. 9, 2025
Registration Advertised: March 23
For further details contact Davies Collison Cave Pty. Ltd. .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2583203.
Disclaimer: Curated by HT Syndication.
